Skip to main content
. 2024 Jan 26;48(2):279–289. doi: 10.4093/dmj.2023.0225

Fig. 2.

Fig. 2.

Prescription rate of sodium-glucose cotransporter 2 inhibitor (SGLT2i) or glucagon-like peptide 1 receptor agonist (GLP1RA) in the patients with established cardiovascular disease during 9.7 months follow-up after events according to (A) cause of event and (B) department managing diabetes. IHD, ischemic heart disease; PAD, peripheral artery disease; HHF, hospitalization for heart failure.